{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T17:43:42Z","timestamp":1765993422545,"version":"3.38.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ctro.2024.100737","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T03:06:24Z","timestamp":1705979184000},"page":"100737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early radiologic and metabolic tumour response assessment during combined chemo-radiotherapy for locally advanced NSCLC"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-1678","authenticated-orcid":false,"given":"Marie","family":"Tvilum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Marquard","family":"Knap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3575-0421","authenticated-orcid":false,"given":"Lone","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza Ahmed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2792-9218","authenticated-orcid":false,"given":"Ane L.","family":"Appelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ate","family":"Haraldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Alber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3548-3527","authenticated-orcid":false,"given":"Cai","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hj\u00f8rdis Hjalting","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9762-1695","authenticated-orcid":false,"given":"Maria","family":"Kandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Ingerslev","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina Maria","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ditte Sloth","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100737_b0005","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0010","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2024.100737_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctro.2024.100737_b0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2022.01.039","article-title":"Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy","volume":"168","author":"M\u00f8ller","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0035","article-title":"18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): results from a randomised clinical trial","volume":"109492","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0040","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.2967\/jnumed.111.102566","article-title":"Response assessment using 18 F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer","volume":"53","author":"van Elmpt","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctro.2024.100737_b0045","article-title":"Prognostic value of early fluorodeoxyglucose-positron emission tomography response imaging and peripheral immunologic biomarkers: substudy of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer","volume":"7","author":"Bowen","year":"2022","journal-title":"Adv Rad Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2018.10.006","article-title":"Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer","volume":"132","author":"Kong (Spring)","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0055","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2967\/jnumed.112.116921","article-title":"18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy","volume":"54","author":"Usmanij","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctro.2024.100737_b0060","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/1754-9485.12427","volume":"60","author":"Fledelius","year":"2016","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.radonc.2016.01.009","article-title":"Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer","volume":"118","author":"Nyg\u00e5rd","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.radonc.2021.04.009","article-title":"The dynamics and prognostic value of FDG PET-metrics in weekly monitoring of (chemo)radiotherapy for NSCLC","volume":"160","author":"La Fontaine","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.radonc.2017.11.023","article-title":"Serial 4DCT\/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy","volume":"126","author":"Bissonnette","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0080","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2967\/jnumed.114.142919","article-title":"Value of metabolic tumor volume on repeated 18 F-FDG PET\/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"55","author":"Huang","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctro.2024.100737_b0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.radonc.2017.08.007","article-title":"Mid-radiotherapy PET\/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer","volume":"125","author":"Gensheimer","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0090","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10147-016-0982-0","article-title":"Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy","volume":"21","author":"Kanzaki","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0095","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2014.03.038","article-title":"Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography","volume":"89","author":"Brink","year":"2014","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100737_b0100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2007.13.9550","volume":"26","author":"Dooms","year":"2008","journal-title":"JCO"},{"key":"10.1016\/j.ctro.2024.100737_b0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/JTO.0b013e3182774108","article-title":"Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non\u2013small-cell lung cancer after neoadjuvant chemotherapy","volume":"8","author":"William","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0110","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ijrobp.2009.02.053","article-title":"Does Response to induction chemotherapy predict survival for locally advanced non\u2013small-cell lung cancer? Secondary analysis of RTOG 8804\/8808","volume":"76","author":"McAleer","year":"2010","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100737_b0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2016.08.019","article-title":"Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose","volume":"121","author":"M\u00f8ller","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2015.06.009","article-title":"Anatomical landmarks accurately determine interfractional lymph node shifts during radiotherapy of lung cancer patients","volume":"116","author":"Hoffmann","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/RLU.0000000000003774","article-title":"Reliability of quantitative 18F-FDG PET\/CT imaging biomarkers for classifying early response to chemoradiotherapy in patients with locally advanced non-small cell lung cancer","volume":"46","author":"Horn","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ctro.2024.100737_b0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.111.101733","article-title":"Noise considerations for PET quantification using maximum and peak standardized uptake value","volume":"53","author":"Lodge","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctro.2024.100737_b0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnmt.115.161745","article-title":"Influence of statistical fluctuation on reproducibility and accuracy of SUV max and SUV peak: a phantom study","volume":"43","author":"Akamatsu","year":"2015","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.ctro.2024.100737_b0140","doi-asserted-by":"crossref","unstructured":"Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. The Oncologist 2018;23:844\u2013848. https:\/\/doi.org\/10.1634\/theoncologist.2017-0659.","DOI":"10.1634\/theoncologist.2017-0659"},{"key":"10.1016\/j.ctro.2024.100737_b0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtho.2017.12.011","article-title":"A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer","volume":"13","author":"Nyg\u00e5rd","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11604-021-01091-y","article-title":"Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer","volume":"39","author":"Katagiri","year":"2021","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.ctro.2024.100737_b0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.radonc.2019.08.003","article-title":"Is tumour sphericity an important prognostic factor in patients with lung cancer?","volume":"143","author":"Davey","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0160","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"Image biomarker standardisation initiative","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.ctro.2024.100737_b0165","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.cllc.2018.08.018","article-title":"Significance of 18F-FDG PET parameters according to histologic subtype in the treatment outcome of stage III non\u2013small-cell lung cancer undergoing definitive concurrent chemoradiotherapy","volume":"20","author":"Kim","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctro.2024.100737_b0170","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/JTO.0b013e31815bdc0d","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer","volume":"2","author":"Shepherd","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0175","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/JTO.0000000000000286","article-title":"Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma","volume":"9","author":"Schuurbiers","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2024.100737_b0180","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT","volume":"20","author":"H\u00f6rner-Rieber","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctro.2024.100737_b0185","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.21037\/tlcr-21-265","article-title":"Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review","volume":"10","author":"Mentink","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctro.2024.100737_b0190","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:42:15Z","timestamp":1742179335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":38,"alternative-id":["S2405630824000144"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100737","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early radiologic and metabolic tumour response assessment during combined chemo-radiotherapy for locally advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100737"}}